| Product Code: ETC6735709 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Acute Myeloid Leukemia Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Acute Myeloid Leukemia Market Revenues & Volume, 2021 & 2031F |
3.3 China Acute Myeloid Leukemia Market - Industry Life Cycle |
3.4 China Acute Myeloid Leukemia Market - Porter's Five Forces |
3.5 China Acute Myeloid Leukemia Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 China Acute Myeloid Leukemia Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 China Acute Myeloid Leukemia Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 China Acute Myeloid Leukemia Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 China Acute Myeloid Leukemia Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 China Acute Myeloid Leukemia Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of acute myeloid leukemia (AML) in China due to aging population and environmental factors |
4.2.2 Growing investments in healthcare infrastructure and research development for AML treatments |
4.2.3 Rising awareness and early diagnosis of AML leading to higher treatment rates |
4.3 Market Restraints |
4.3.1 High cost of AML treatments and limited insurance coverage in China |
4.3.2 Lack of access to advanced therapies and specialized healthcare facilities in certain regions |
4.3.3 Regulatory challenges and approval delays for new AML drugs in the Chinese market |
5 China Acute Myeloid Leukemia Market Trends |
6 China Acute Myeloid Leukemia Market, By Types |
6.1 China Acute Myeloid Leukemia Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 China Acute Myeloid Leukemia Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 China Acute Myeloid Leukemia Market Revenues & Volume, By Myeloblastic, 2021- 2031F |
6.1.4 China Acute Myeloid Leukemia Market Revenues & Volume, By Promyelocytic, 2021- 2031F |
6.1.5 China Acute Myeloid Leukemia Market Revenues & Volume, By Myelomonocytic, 2021- 2031F |
6.2 China Acute Myeloid Leukemia Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 China Acute Myeloid Leukemia Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.2.3 China Acute Myeloid Leukemia Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.2.4 China Acute Myeloid Leukemia Market Revenues & Volume, By Immunotherapy, 2021- 2031F |
6.2.5 China Acute Myeloid Leukemia Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.2.6 China Acute Myeloid Leukemia Market Revenues & Volume, By Others, 2021- 2031F |
6.3 China Acute Myeloid Leukemia Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 China Acute Myeloid Leukemia Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 China Acute Myeloid Leukemia Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 China Acute Myeloid Leukemia Market Revenues & Volume, By Others, 2021- 2031F |
6.4 China Acute Myeloid Leukemia Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 China Acute Myeloid Leukemia Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 China Acute Myeloid Leukemia Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 China Acute Myeloid Leukemia Market Revenues & Volume, By Speciality Centres, 2021- 2031F |
6.4.5 China Acute Myeloid Leukemia Market Revenues & Volume, By Others, 2021- 2031F |
6.5 China Acute Myeloid Leukemia Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 China Acute Myeloid Leukemia Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 China Acute Myeloid Leukemia Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 China Acute Myeloid Leukemia Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 China Acute Myeloid Leukemia Market Import-Export Trade Statistics |
7.1 China Acute Myeloid Leukemia Market Export to Major Countries |
7.2 China Acute Myeloid Leukemia Market Imports from Major Countries |
8 China Acute Myeloid Leukemia Market Key Performance Indicators |
8.1 Average time to diagnose AML cases in China |
8.2 Patient survival rates post-AML treatment |
8.3 Percentage of AML patients receiving targeted therapy |
8.4 Adoption rate of innovative treatment modalities for AML |
8.5 Number of clinical trials for AML therapies conducted in China |
9 China Acute Myeloid Leukemia Market - Opportunity Assessment |
9.1 China Acute Myeloid Leukemia Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 China Acute Myeloid Leukemia Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 China Acute Myeloid Leukemia Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 China Acute Myeloid Leukemia Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 China Acute Myeloid Leukemia Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 China Acute Myeloid Leukemia Market - Competitive Landscape |
10.1 China Acute Myeloid Leukemia Market Revenue Share, By Companies, 2024 |
10.2 China Acute Myeloid Leukemia Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here